Better Health for All

Protara Therapeutics is a clinical-stage biopharmaceutical company focused on developing transformative therapies for rare and life-threatening diseases, such as non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations.

This indicates that 100% of its product portfolio is dedicated to delivering health benefits. The company's entire R&D is dedicated to health improvement through the development of TARA-002, an investigational cell therapy. The company is conducting a Phase 2 open-label clinical trial for TARA-002 in NMIBC patients with high-grade carcinoma in situ, demonstrating engagement in clinical research.

Fair Money & Economic Opportunity

Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare and life-threatening diseases.

The provided articles discuss the company's clinical programs, drug development pipeline, and public offerings to fund these programs. There is no evidence that the company engages in financial services, lending, or any activities related to providing money, insurance, or financial products to consumers. Therefore, all KPIs under the 'Fair Money & Economic Opportunity' value are not applicable to the company's core business operations, and no specific, concrete data points were found to score any of these KPIs.

Honest & Fair Business

Protara Therapeutics has not reported any regulatory fines in the past three years, with explicit statements that no unlawful payments have been made, no violations of the U.S. Foreign Corrupt Practices Act, and no pending or threatened actions regarding Anti-Money Laundering Laws.

The company has a Code of Business Conduct and Ethics and a dedicated, toll-free compliance hotline and website portal (https://www.whistleblowerservices.com/TARA) for reporting suspected violations, which allows for anonymous messages and explicitly prohibits retaliation. The company also states that it has not had any material weakness in internal control over financial reporting since its most recent fiscal year. The company has not had any financial restatements, and its financial statements are certified by an independent auditor, Ernst & Young LLP. The company has an anti-corruption policy that complies with the U.S. Foreign Corrupt Practices Act and other international laws, and prohibits facilitation payments. However, the company relies on third-party contract manufacturing organizations (CDMOs) and contract research organizations (CROs) which are subject to cGMP and GCP regulations, and mentions third-party risk management processes, but does not provide a percentage of ethical claims independently verified. There is no specific information on the percentage of board members free from material conflicts of interest or the percentage of revenue, assets, or subsidiaries covered by independent external audit.

Kind to Animals

Protara Therapeutics' primary products, TARA-002 and IV Choline Chloride, do not use animal-derived ingredients. TARA-002 is described as a cell-based therapy developed from a master cell bank of Streptococcus pyogenes (a bacterium), and IV Choline Chloride is a chemical compound.

No other animal inputs are mentioned in the provided articles regarding the company's product lines.

Safe & Smart Tech

Protara Therapeutics reported a cyber-attack on its email server in Q1 2020.

However, as of December 2025, the company states there have been no security breaches or compromises of IT systems and data that would reasonably be expected to have a Material Adverse Effect, and no breaches of personal data except those remedied without material cost or notification duty. This indicates no significant breaches in the past three years. The company conducts ongoing cybersecurity user awareness training and utilizes industry-standard encryption protocols. It performs periodic vulnerability scanning and an annual cyber risk management program assessment against the NIST CSF, with a risk mitigation plan to address identified vulnerabilities. Protara also monitors IT assets, data, and services. The company states it is in material compliance with all applicable data privacy and security laws and regulations, including GDPR, and has privacy policies in place. It has established a compliance officer and a whistleblowing hotline/website for reporting violations. Protara uses identity access management controls, including restricted access to privileged accounts. However, the privacy policy indicates users must contact the company to exercise data rights, suggesting a less streamlined process than a comprehensive privacy dashboard. Data retention is described as necessary for the purpose of collection, which is a standard approach. The company does not knowingly collect personal data from children under 16.

Zero Waste & Sustainable Products

The provided articles do not contain any specific, quantitative data points related to waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability scores, waste audit frequency, zero waste certifications, waste disposal violations, material efficiency, packaging to product ratio, waste reduction targets, supplier waste requirements, or customer waste education.

Therefore, no KPIs under the 'Zero Waste & Sustainable Products' value can be assessed.